William Forbes

William Forbes

Company: Trevi Therapeutics

Job title: Chief Development Officer


Nalbuphine ER, an Oral Dual Acting Opioid being Developed for the Treatment of Pruritus associated with Prurigo Nodularis 2:00 pm

• Examining the role of Nal ER in attenuating the itch scratch cycle by rebalancing the KOR and MOR pathways • Evaluating efficacy and safety of Nal ER in the treatment of pruritus: Phase 2 results in prurigo nodularis and Phase 3 results in Uremic Pruritus • Discussing ongoing Phase 2b/3 clinical study for Nal…Read more

day: Day 2 PM - Track 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.